[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A, Pollock RE, Lev D: Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res; 2008 Sep 1;14(17):5466-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
  • PURPOSE: Soft tissue sarcoma (STS) is a rare heterogeneous malignancy.
  • Overall survival has been stagnant for decades, primarily because systemic therapies are ineffective versus metastases, the leading cause of STS lethality.
  • Consequently, we examined whether tyrosine kinase receptors active in STS growth signaling might be blockable and whether multireceptor blockade might synergize with low-dose STS chemotherapy by therapeutically affecting STS cells and their associated microenvironment.
  • EXPERIMENTAL DESIGN: Vandetanib (AstraZenca), a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, was evaluated alone and with chemotherapy in vitro and in vivo in three human STS nude mouse xenograft models of different STS locations (muscle, uterus, lung), stages (primary, metastatic), and subtypes (leiomyosarcoma, fibrosarcoma, uterine sarcoma: luciferase-expressing MES-SA human uterine sarcoma cells surgically implanted into uterine muscularis with bioluminescence tumor growth assessment; developed by us).
  • Vandetanib alone and with chemotherapy statistically significantly inhibited leiomyosarcoma local growth and fibrosarcoma lung metastasis.
  • Direct injection of MES-SA into nude mice uterine muscularis resulted in high tumor take (88%), whereas s.c. injection resulted in no growth, suggesting microenvironmental tumor growth modulation.
  • Vandetanib alone and with chemotherapy statistically significantly inhibited uterine sarcoma growth.
  • Given the urgent need for better systemic approaches to STS, clinical trials evaluating vandetanib, perhaps with low-dose chemotherapy, seem warranted.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Muscle Neoplasms / drug therapy. Piperidines / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Mice. Mice, Nude. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18765538.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


2. Oosten AW, Seynaeve C, Schmitz PI, den Bakker MA, Verweij J, Sleijfer S: Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin. Sarcoma; 2009;2009:348910

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin.
  • Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs).
  • In this retrospective study we investigated the outcome of first line chemotherapy in 65 patients with unresectable or metastatic LMS.
  • No statistically significant differences in outcomes for uterine and non-uterine LMS were found.
  • In non-uterine LMS, however, the PFS and OS seemed to be longer for females than for males, potentially negatively affecting outcomes in this group.
  • If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5269-74 [18809609.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2034-7 [10570428.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1585-91 [18278813.001]
  • [Cites] Oncologist. 2007 Nov;12(11):1351-60 [18055856.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):59-61 [16462504.001]
  • [Cites] Oncologist. 2005 Nov-Dec;10(10):833-41 [16314294.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1426-30 [15919202.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):644-7 [14766260.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3225-9 [12115355.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Anticancer Drugs. 2000 Jun;11(5):325-9 [10912948.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):177-81 [10663634.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2433-6 [18771914.001]
  • (PMID = 20066161.001).
  • [ISSN] 1369-1643
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2801456
  •  go-up   go-down


3. Harrison L, Blackwell K: Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist; 2004;9 Suppl 5:31-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?
  • Hypoxia and anemia (which contributes to tumor hypoxia) can lead to ionizing radiation and chemotherapy resistance by depriving tumor cells of the oxygen essential for the cytotoxic activities of these agents.
  • Hypoxia may also reduce tumor sensitivity to radiation therapy and chemotherapy through one or more indirect mechanisms that include proteomic and genomic changes.
  • These effects, in turn, can lead to increased invasiveness and metastatic potential, loss of apoptosis, and chaotic angiogenesis, thereby further increasing treatment resistance.
  • Investigations of the prognostic significance of pretreatment tumor oxygenation status have shown that hypoxia (oxygen tension [pO(2)] value < or =10 mmHg) is associated with lower overall and disease-free survival, greater recurrence, and less locoregional control in head and neck carcinoma, cervical carcinoma, and soft-tissue sarcoma.
  • In view of the deleterious effect of hypoxia on standard cancer treatment, a variety of hypoxia- and anemia-targeted therapies have been studied in an effort to improve therapeutic effectiveness and patient outcomes.
  • Early evidence from experimental and clinical studies suggests the administration of recombinant human erythropoietin (rHuEPO) may enhance the effectiveness of radiation therapy and chemotherapy by increasing hemoglobin levels and ameliorating anemia in patients with disease- or treatment-related anemia.
  • However, further research is needed in the area of hypoxia-related treatment resistance and its reversal.
  • [MeSH-major] Anemia / complications. Anemia / etiology. Cell Hypoxia. Erythropoietin / pharmacology. Erythropoietin / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Sarcoma / drug therapy. Sarcoma / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Hemoglobins. Humans. Radiation Tolerance


Advertisement
4. Talbot SM, Keohan ML, Hesdorffer M, Orrico R, Bagiella E, Troxel AB, Taub RN: A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer; 2003 Nov 1;98(9):1942-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma.
  • BACKGROUND: The objective of this study was to assess the efficacy and toxicity of the imidazotetrazine derivative temozolomide for patients with unresectable or metastatic soft tissue sarcoma.
  • All responding patients had leiomyosarcoma of uterine or nonuterine origin; and, in a subset analysis of these patients, the objective response rate was 18% (2 of 11 patients), with disease stabilization occurring in 3 of 11 patients (27%).
  • There were no treatment-related deaths or National Cancer Institute Grade 4 toxicities.
  • CONCLUSIONS: Temozolomide at the dose schedule employed in the current study was tolerated well and had modest activity against previously treated unresectable or metastatic leiomyosarcoma of both uterine and nonuterine origin.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / secondary. Male. Middle Aged. Prognosis. Treatment Outcome. Uterine Neoplasms / drug therapy. Uterine Neoplasms / secondary

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 14584078.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


5. Grimer R, Judson I, Peake D, Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma; 2010;2010:506182

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the management of soft tissue sarcomas.
  • These guidelines were drawn up following a consensus meeting of UK sarcoma specialists convened under the auspices of the British Sarcoma Group and are intended to provide a framework for the multidisciplinary care of patients with soft tissue sarcomas.
  • Note was also taken of the National Institute for Health and Clinical Excellence (NICE) improving outcomes guidance (IOG) for people with sarcoma and existing technology appraisals.
  • The guidelines are not intended to challenge NICE guidance but discrepancies may exist where current guidance does not reflect an international standard of care owing to the ever-evolving nature of cancer treatment.
  • Any patient with a suspected soft tissue sarcoma should be referred to a diagnostic centre and managed by a specialist sarcoma multidisciplinary team.
  • Pre-operative treatment with chemotherapy or radiotherapy should be considered for patients with borderline resectable tumours.
  • Adjuvant chemotherapy is not routinely recommended but may be considered in certain specific situations.
  • Regular follow up is recommended to assess local control and the development of metastatic disease.
  • Single agent doxorubicin is the standard first line therapy for metastatic disease.
  • Combination therapy may be considered in individual patients.
  • There is specific guidance on the management of retroperitoneal and uterine sarcomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):361-6 [15948172.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):371-9 [16752414.001]
  • [Cites] CA Cancer J Clin. 2006 Sep-Oct;56(5):282-91; quiz 314-5 [17005597.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):230-8 [17066234.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Treat Rev. 2007 Nov;33(7):603-8 [17250970.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1588-94 [17987032.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii89-93 [18456783.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):573-81 [18521899.001]
  • [Cites] Eur J Cancer. 2008 Sep;44(13):1841-5 [18640829.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2433-6 [18771914.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4188-96 [19652065.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1159-62 [9426338.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):871-6 [9789610.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Science. 1999 Dec 24;286(5449):2528-31 [10617473.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] Ann R Coll Surg Engl. 2001 May;83(3):203-5 [11432141.001]
  • [Cites] J Bone Joint Surg Br. 2001 Nov;83(8):1149-55 [11764430.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4472-7 [12431971.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2397-406 [12460784.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):64-9 [12504660.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):170-6 [12821359.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):429-37 [12850194.001]
  • [Cites] Curr Opin Oncol. 2003 Jul;15(4):319-26 [12874511.001]
  • [Cites] Clin Experiment Ophthalmol. 2003 Oct;31(5):392-6 [14516425.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2584-99 [14642921.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2622-31 [14642924.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] Br J Surg. 2004 Dec;91(12):1624-9 [15505878.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):437-44 [15653701.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2853-60 [16289617.001]
  • (PMID = 20634933.001).
  • [ISSN] 1369-1643
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2903951
  •  go-up   go-down


6. Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Penel N, Blay JY, Groupe Sarcome Français: Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer; 2006 Aug 1;119(3):706-11
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
  • Advanced soft-tissue sarcomas are usually resistant to cytotoxic agents such as doxorubicin and ifosfamide.
  • We conducted a retrospective study on 133 patients (58 males/75 females) with unresectable or metastatic soft-tissue sarcoma.
  • The initial localizations were limb (44), uterine (32), retroperitoneal (23) and organs or bone (34).
  • No difference was found between uterine soft-tissue sarcomas versus others.
  • Response to treatment and overall survival were better for patients in World Health Organization (WHO) performance status classification (PS) 0 at baseline versus patients in WHO PS-1, 2 or 3 (p=0.023 and p<10(-4), respectively).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Diarrhea / chemically induced. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Male. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Retrospective Studies. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Thrombocytopenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • [ErratumIn] Int J Cancer. 2007 Jan 15;120(2):450. Penel, Nicolas [added]
  • (PMID = 16496406.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


7. Lin JF, Slomovitz BM: Uterine sarcoma 2008. Curr Oncol Rep; 2008 Nov;10(6):512-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine sarcoma 2008.
  • Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers.
  • The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma.
  • Most patients with uterine sarcomas are middle- to older-aged women who present with abnormal uterine bleeding or pelvic mass, which may be confused with leiomyoma.
  • Surgery--including hysterectomy and resection of disease--serves as the main treatment modality.
  • Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature.
  • For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response.
  • For patients with uterine sarcomas, enrollment in clinical trials is strongly encouraged.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy
  • [MeSH-minor] Carcinosarcoma / diagnosis. Carcinosarcoma / therapy. Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Female. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / therapy. Medical Oncology / methods. Neoplasm Metastasis. Recurrence. Research Design. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Feb 15;112(4):820-30 [18189292.001]
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):417-24 [3945454.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):513-7 [17935762.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):939-44 [9625851.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):270-94 [8001001.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):176-86 [12833470.001]
  • [Cites] Gynecol Oncol. 2008 Jul;110(1):43-8 [18445505.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):535-58 [8179071.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(4):370-4 [17009628.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1200-1 [18217961.001]
  • [Cites] Gynecol Oncol. 1998 Jan;68(1):8-13 [9454652.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):323-8 [18394689.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2170-82 [7127257.001]
  • [Cites] Arch Gynecol Obstet. 2002 Apr;266(2):92-5 [12049303.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Obstet Gynecol. 1994 Jun;83(6):1015-20 [8190416.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):25-32 [8690287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):739-48 [11172957.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(6):541-6 [10215437.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):821-7 [9311600.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2239-47 [3179938.001]
  • [Cites] Adv Anat Pathol. 2000 Sep;7(5):257-81 [10976906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):47-52 [10219793.001]
  • [Cites] Hum Pathol. 1990 Feb;21(2):223-7 [2307449.001]
  • [Cites] Obstet Gynecol. 1994 Mar;83(3):414-8 [8127535.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1972-9 [9806656.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2127-30 [3793549.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):204-8 [15047237.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):370-5 [7705670.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):253-7 [9648597.001]
  • [Cites] Br J Radiol. 1993 Nov;66(791):1009-15 [8281375.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):630-4 [17320937.001]
  • [Cites] Hum Pathol. 1970 Sep;1(3):331-49 [4330001.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):369-73 [7997731.001]
  • [Cites] Cancer. 1978 Sep;42(3):1161-70 [698911.001]
  • [Cites] Gynecol Oncol. 1996 Nov;63(2):247-53 [8910635.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):313-5 [18534248.001]
  • (PMID = 18928666.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


8. Pautier P, Genestie C, Fizazi K, Morice P, Mottet C, Haie-Meder C, Le Cesne A, Lhommé C: Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer; 2002 Nov-Dec;12(6):749-54
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
  • Uterine sarcomas are an extremely rare event.
  • There is no standard therapy for cases of relapse, although chemotherapy is commonly used.
  • We studied the use of a cisplatin-based chemotherapy regimen for uterine sarcomas with an unusually long follow-up.
  • Group 1 consisted of patients undergoing adjuvant therapy (for initial disease, eight patients; for pelvic recurrence, two patients); Group 2 consisted of patients with advanced disease (locoregional after initial local therapy, five patients; local recurrence, six patients) or metastatic disease (stage IV, four patients; recurrence, 14 patients).
  • DECAV therapy consisted of doxorubicin 50 mg/m2 d1, dacarbazine (DTIC) 200 mg/m2/d d1-3, vindesine 2 mg/day d1-2, cisplatin 100 mg/m2 d3, and either cyclophosphamide (CPM) 200 mg/m2/d d1-3 (n = 21), or ifosfamide (IFM) 2 g/m2/d d1-3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia (nine patients), including 13 cases of febrile neutropenia.
  • We conclude that the DECAV regimen is clearly active in uterine sarcomas but is too toxic to be recommended routinely.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Blood Transfusion. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Carcinosarcoma / secondary. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. France. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Middle Aged. Neoplasm Staging. Neutropenia. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / mortality. Sarcoma, Endometrial Stromal / secondary. Survival Analysis. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445254.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; DECAV protocol
  •  go-up   go-down


9. Pautier P, Rey A, Haie-Meder C, Kerbrat P, Dutel JL, Gesta P, Bryard F, Morice P, Duvillard P, Lhommé C: Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int J Gynecol Cancer; 2004 Nov-Dec;14(6):1112-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone.
  • Uterine sarcoma is a poor prognosis disease, with a high risk of metastatic relapse.
  • We conducted a study of adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy (n=18).
  • The results were then compared in a matched case-controlled study to radiotherapy alone (n=16) or no therapy at all (n=2).
  • Chemotherapy consisted in three cycles of adriamyein-platinum-ifosfamide (API) (doxorubicin 60 mg /m2 on day 1; cisplatin 100 mg /m2 on day 2; ifosfamide 5 g /m2 on day 1+mesna 5 g /m2 on day 1+granulocyte colony-stimulating factor; q 3 weeks).
  • Drug doses were reduced (20% for ifosfamide and cisplatin) four times (four patients) due to hematologic toxicity.
  • Compared to a case-control study of adjuvant radiotherapy alone, results were not decreased by the addition of a toxic chemotherapy.
  • CONCLUSION: Adjuvant API chemotherapy followed by radiotherapy is a feasible protocol; a multicenter phase III study comparing radiotherapy alone versus API chemotherapy followed by radiotherapy just began in France.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Case-Control Studies. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. France. Humans. Ifosfamide / administration & dosage. Leiomyosarcoma / diagnosis. Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Leiomyosarcoma / radiotherapy. Middle Aged. Neoadjuvant Therapy. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15571617.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


10. Kanjeekal S, Chambers A, Fung MF, Verma S: Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol; 2005 May;97(2):624-37
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.
  • OBJECTIVE: To conduct a systematic review of the literature regarding the systemic treatment of advanced uterine sarcoma and provide an evidence-based summary of the available literature.
  • "Uterine sarcoma," "leiomyosarcoma," "mixed mesodermal tumor," "chemotherapy," and "systemic therapy" were combined with the search terms for study designs.
  • In a randomized trial of doxorubicin versus doxorubicin plus cyclophosphamide for advanced or recurrent uterine sarcoma, doxorubicin produced an overall response rate (RR) of 19% and median survival of 11.6 months, which was similar to the response with combination chemotherapy (RR 19%, median survival 10.9 months).
  • A randomized trial comparing doxorubicin to doxorubicin with dacarbazine in women with advanced or recurrent uterine sarcoma demonstrated a significantly higher RR with the combination (P < 0.05), but no significant difference in survival.
  • CONCLUSIONS: Offering palliative chemotherapy to patients with advanced, unresectable uterine sarcoma who are symptomatic from this disease is a reasonable decision.
  • Doxorubicin is an option for women with advanced uterine sarcoma.
  • The combination of cisplatinum and ifosfamide is also an option for women with metastatic mixed mesodermal tumors; however, this combination is associated with significant toxicity when compared to ifosfamide alone.
  • [MeSH-major] Mixed Tumor, Mesodermal / drug therapy. Sarcoma, Endometrial Stromal / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Female. Humans. Leiomyosarcoma / drug therapy. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863170.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


11. Saâdi I, Errihani H, Haddadi K, Amaoui B, Benjaafar B, El Gueddari BK: [Sarcoma botryoïde of the uterine cervix: report of a case]. Cancer Radiother; 2002 Dec;6(6):363-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcoma botryoïde of the uterine cervix: report of a case].
  • Botryoïde sarcoma of the uterine cervix is a very rare tumor of the young woman or during genial activity.
  • The treatment ranged from radical surgery to conservative surgery followed by chemotherapy.
  • We report a case of cervical botryoide rhabdomyosarcoma occurred in a 33 year-old woman treated primary by chemotherapy followed by surgery and adjuvant chemotherapy.
  • The patient died by extensive metastatic retroperitoneal nodes and lung.
  • [MeSH-major] Neoplasm Metastasis. Rhabdomyosarcoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504774.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Shamseddine A, Taher A, Abou-Mourad Y, Seoud M, Khalil A: Cure of metastatic uterine carcinosarcoma to lungs: a case report. Int J Gynecol Cancer; 2003 Jan-Feb;13(1):88-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cure of metastatic uterine carcinosarcoma to lungs: a case report.
  • Most patients with advanced or recurrent uterine sarcoma experience disease progression and ultimately die.
  • We present a case of uterine sarcoma with lung metastasis treated with systemic chemotherapy and with no evidence of disease for more than 5 years.
  • After four cycles of systemic chemotherapy with cisplatin and ifosfamide, the pulmonary nodules completely disappeared.
  • Currently she is still in complete remission after more than 5 years, but unfortunately she has developed myelodysplastic syndrome.
  • This is the first reported case in the literature of cured metastatic uterine carcinosarcoma to lungs, with long-term survival of 5 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Ifosfamide / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12631227.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Benoit L, Arnould L, Cheynel N, Goui S, Collin F, Fraisse J, Cuisenier J: The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol; 2005 May;31(4):434-42
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgery and treatment trends in uterine sarcoma.
  • AIMS: To report a series of uterine sarcomas treated in one institution.
  • METHODS: We report 72 cases of uterine sarcomas treated in a single institution, comparing the periods 1966-1989 and 1990-2001.
  • The parameters studied were histological type, tumour stage and treatment.
  • The control of pelvic, local and/or metastatic disease were also studied.
  • RESULTS: The histological types consisted in 34 leiomyosarcomas, 25 mixte mullerian tumours, 12 endometrial stromal sarcoma and one angiosarcoma.
  • The proportion, of stage I was lower in 1966-1989 than in 1990-2002.
  • The percentage of second-line surgery (post-radiotherapy or -chemotherapy) rose from 2.2% in 1966-1989 to 19.2% in 1990-2002.
  • Chemotherapy was administered in 37.5% of cases with also no difference between the two periods.
  • The overall 5-year survival by stage was 47.5% for stage I, 60.6% for stage II and 15.0% for stages III and IV.
  • The 5-year pelvic disease control by FIGO stage was 66.6% for stage I, 62.5% for stage II and 18% for the more advanced stages.
  • CONCLUSION: Surgery remains the reference treatment.
  • Local and regional disease control, as adjuvant therapies do not seem to decrease the risk of metastatic spread or increase survival.
  • [MeSH-major] Sarcoma / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837053.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Murakami M, Tsukada H, Ikeda M, Watanabe M, Muramatsu T, Miyamoto T, Makino T, Yasuda S, Ide M, Nasu S: Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma.
  • : 5100 Background: Uterine sarcomas are relatively rare and its prognosis is poor.
  • About half of patients with stage I will have distant metastasis within two years after the complete operations.
  • Accurate diagnosis of the metastatic sites is important for the treatment strategy.
  • Unfortunately current diagnostic techniques, including CT, MRI, and ultrasonography (US) are not efficient for the detection of recurrence.
  • There is little report of the experience with whole-body 18 fluorodeoxyglucose (FDG)-PET for the detection of recurrence in the follow up of patients with uterine sarcomas.
  • The purpose of this study is to evaluate the availability of FDG-PET for the detection of recurrence in patients with uterine sarcomas.
  • METHODS: Twelve patients with pathologically proven uterine sarcomas (nine leiomyosarcoma and three carcinosarcoma) took FDG-PET, CT, MRI and US for the purpose of the detection of recurrence after the primary treatment.
  • Positive results of PET scan did not affect the prognosis in four patients, but another patient with solitary intraperitoneal tumor by PET scan could received the chemotherapy and operation, which histologically confirmed the recurrence of leiomyosarcoma.
  • Application of PET scan for the early detection of recurrence may affect the prognosis of some patients with uterine sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Grosso F, Sanfilippo R, Jones RL, Collini P, Morosi C, Raspagliesi F, Tercero JC, D'Incalci M, Judson IR, Casali PG: Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM). J Clin Oncol; 2009 May 20;27(15_suppl):10530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM).
  • T has been approved in Europe for second line treatment of advanced soft tissue sarcomas (STS).
  • These differences may be responsible for the sensitivity of this subtype to therapy, thus justifying an evaluation of the activity of T in a relatively homogeneous series of U-LM patients.
  • METHODS: From April 2000, 56 patients (pts) with advanced disease, previously exposed to a median of 3 chemotherapy lines (range 1-5), received T within an expanded access programme at two European referral institutions for sarcoma.
  • The clinical records were reviewed focusing on response and treatment outcome.
  • Median age was 56 yrs (range 29-73), median number of metastatic sites was 2 (range 1-4), the most frequent metastatic site was lung (88%), 24 patients had a local relapse.
  • CONCLUSIONS: These results compare favourably with other systemic treatments in advanced U-LMS and support their sensitivity to T.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963908.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Morgan JA, George S, Desai J, St Amand M, Horton D, Wilkins E, Manola J, Demetri GD: Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS). J Clin Oncol; 2004 Jul 15;22(14_suppl):9009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS).
  • : 9009 Background: Both single agent gemcitabine and vinorelbine have efficacy for treatment of STS.
  • Combination GV is active therapy for metastatic carcinoma, with acceptable toxicity.
  • This single institution phase II trial has been undertaken to determine response rates and toxicity of combination GV for treatment of metastatic STS.
  • METHODS: Pts with PS 0-2, unresectable or metastatic STS, adequate end organ function, and no more than 1 prior regimen were eligible.
  • RESULTS: An initial 18 pts have been accrued, following standard two-stage design by the method of Simon.
  • Histology was uterine or extremity leiomyosarcoma (LMS) in 9, high grade pleomorphic sarcoma in 2, and 1 each with carcinosarcoma, pleomorphic liposarcoma, malignant peripheral nerve sheath tumor (MPNST), desmoplastic small round cell tumor, rhabdomyosarcoma, and small round cell sarcoma.
  • No treatment related deaths have occurred.
  • Of the remaining 9, 4 have been treatment related, including cough, nausea, vomiting, and SGPT elevation.
  • There have been two confirmed PRs, one high grade uterine LMS progressing after single agent doxorubicin, and one small round cell tumor recurring within 6 months of completion of a 5 drug Ewing's regimen.
  • One metastatic MPNST has exhibited stable disease for greater than 4 months.
  • Median time to progression has been 4.2 months and median survival 6.25 months.
  • CONCLUSIONS: GV appears to be a well-tolerated and potentially effective regimen for first or second line treatment of metastatic STS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013692.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kanjeekal S, Chambers A, Fung Kee Fung M, Verma S, Cancer Care Ontario's Practice Guidelines Initiative Gynecology Cancer Disease Site Group, Ontario: Metastatic uterine sarcoma: A systematic review of the literature. J Clin Oncol; 2004 Jul 15;22(14_suppl):5105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine sarcoma: A systematic review of the literature.
  • : 5105 Background: Uterine sarcomas are rare and management of metastatic disease often conforms to treatment practice for other metastatic soft tissue sarcomas.
  • We have conducted a systematic review of systemic chemotherapy in the management of metastatic uterine sarcoma.
  • METHODS: MEDLINE and the Cochrane Library databases, as well as the proceedings from ASCO, were searched for articles that were (1) systematic reviews, practice guidelines, meta-analysis, or randomized controlled trials (RCT) comparing treatment regimens for metastatic uterine sarcoma or (2) prospective phase II trials or retrospective reviews reporting the effects of treatment for > 20 patients.
  • The overall response rate (RR) for single agent doxorubicin (D) was 19% for all sub-types of metastatic uterine sarcomas.
  • D combined with either dimethyl triazenoimidazole carboxamide (DTIC) or cyclophosphamide compared to D alone showed no survival benefit and there was increased toxicity with combination treatment.
  • The two most active single agents for first-line treatment of mixed mesodermal tumours (MMT) were ifosfamide (I) (RR=39% and cisplatinum (C) (RR=19%).
  • In an RCT of first-line treatment of MMT, the combination of I and C compared to I alone, resulted in a higher RR (57% versus 39%) and a small improvement in progression-free survival (6.0 vs 4.0 months, p=0.02).
  • A small phase II study of second-line therapy in patients with leiomyosarcoma (LMS) treated with the combination of gemcitabine and docetaxel reported a RR of 53% and a relatively mild toxicity profile.
  • CONCLUSIONS: There is a paucity of high quality RCTs that examine the role of systemic therapy in patients with metastatic uterine sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Gibbon D, Wagreich A, Nieves-Neira W, Shih W, Ziang W, Rodriguez-Rodriguez L, Germino J: A retrospective review of metastatic or recurrent uterine sarcomas treated with paclitaxel, carboplatin, and gemcitabine chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):5143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of metastatic or recurrent uterine sarcomas treated with paclitaxel, carboplatin, and gemcitabine chemotherapy.
  • : 5143 Background: The prognosis of metastatic uterine sarcoma is poor with median survival reported between 4-26 months.
  • The primary objective of this study was to assess the activity of paclitaxel, carboplatin and gemcitabine (GCP) in the treatment of primary, metastatic, or recurrent uterine sarcomas.
  • The efficacy of the GCP regimen in women with metastatic or recurrent uterine sarcomas was assessed.
  • Patients were treated on a phase II soft tissue sarcoma protocol or off protocol by the gynecologic oncology division.
  • 4 patients were inevaluable; 3 patients for less than one month of therapy and 1 patient without measurable disease.
  • Histology included 6 leiomyosarcomas (LMS), 1 endometrial stromal sarcoma (ESS), and 2 carcinosarcomas (CS).
  • Median time to progression for all patients was 10 months (95% CI {83 -530 days}).
  • CONCLUSIONS: GCP combination chemotherapy demonstrates moderate activity, with acceptable toxicity, in patients with advanced uterine sarcomas.
  • Given the durable median time to progression and overall survival, this pilot data supports the evaluation of this regimen in a multi-institutional phase II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016800.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ihnen M, Mahner S, Jänicke F, Schwarz J: Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):957-63
Genetic Alliance. consumer health - Uterine sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature.
  • Uterine sarcomas are a rare form of uterine cancer.
  • Endometrial stromal sarcoma (ESS) accounts for 0.2% of all gynecological malignancies.
  • Forms of possible treatment include surgery, radiotherapy, chemotherapy, and endocrine treatment.
  • Randomized trials analyzing these treatment options are limited due to the rarity of this disease; therefore, a standard therapy could not be established thus far.
  • To present an overview of the current treatment options of ESS, a search of Medline, Embase, and the Cochrane Library was performed and the results concluded.
  • We report the case of a 32-year-old woman who presented with FIGO stage II ESS.
  • Initial treatment with tamoxifen and local perfusion with cisplatin resulted in disease progression and were discontinued.
  • A novel, therapeutic approach using two cycles of combination chemotherapy with doxorubicin and ifosfamide followed by surgery was applied.
  • Thus, we conclude that although there is no data from randomized trials available, chemotherapy in advanced or metastatic ESS can provide an opportunity for surgical treatment and can lead to long-term remission.
  • [MeSH-major] Endometrial Neoplasms / therapy. Sarcoma, Endometrial Stromal / therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17359294.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


20. Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS: Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol; 2001 Oct;83(1):89-94
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
  • OBJECTIVE: Uterine adenosarcoma with sarcomatous overgrowth (ASSO) is a rare variant of uterine sarcoma first described in 1989.
  • This clinicopathologic study was undertaken to compare the treatment and survival of uterine adenosarcoma with sarcomatous overgrowth to that of uterine carcinosarcomas.
  • METHODS: A review of uterine sarcomas diagnosed at Washington Hospital Center from January 1988 to December 1998 was performed.
  • Records were reviewed for demographic data, surgical staging, primary and adjuvant therapy, metastatic site, disease recurrence, and survival.
  • Statistical analysis included chi(2) test and Student's t test.
  • Kaplan-Meier survival curves were plotted to estimate the median and 5-year survival times.
  • The log-rank test was used to compare survival times.
  • RESULTS: Sixty patients were diagnosed with uterine sarcoma at Washington Hospital Center.
  • Of these, 33 (55%) were uterine carcinosarcomas, 11 (18%) ASSOs, 6 (10%) adenosarcomas, and 10 (17%) leiomyosarcomas.
  • Of the patients diagnosed with uterine ASSO, 3 (27%) were stage I, 3 (27%) stage II, 1 (9%) stage III, and 4 (36%) stage IV.
  • All 11 patients with uterine ASSO underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and tumor debulking.
  • Postoperative adjuvant therapy included chemotherapy (n = 4), radiation (n = 4), combination radiation and chemotherapy (n = 1), and no adjuvant therapy (n = 2).
  • The overall median survival time of patients with uterine ASSO was 13 months.
  • Nine of eleven patients are dead of disease, and two patients (both with stage I) are alive without evidence of disease at 18 and 19 months.
  • Of these, 10 (34%) were stage I, 6 (22%) stage II, 3 (10%) stage III, and 10 (34%) stage IV.
  • Twenty-seven of the twenty-nine patients diagnosed with carcinosarcoma underwent surgical therapy to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, staging and tumor debulking.
  • Two patients died prior to treatment.
  • Postoperative adjuvant therapy included chemotherapy (n = 9), radiation (n = 13), combination (n = 1), and no further therapy (n = 4).
  • Twenty of the twenty-nine patients are dead of disease; there were nine surviving patients at the time of this report (stage I-5, stage II-3, stage III-1).
  • Comparison of the Kaplan-Meier survival curves using the log-rank test suggests a worse prognosis for uterine ASSO.
  • CONCLUSIONS: Patients diagnosed with uterine ASSO have a poor prognosis similar to that of carcinosarcoma.
  • Additional therapy in the form of radiation, chemotherapy, or both has been reported; however, the superiority of one modality could not be determined from our data.
  • [MeSH-major] Adenosarcoma / therapy. Carcinosarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11585418.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dörken B, Reichardt P: Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol; 2006 Jun;101(3):464-9
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
  • Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new cases in the US or EU per year.
  • A higher risk in women receiving estrogen replacement therapy (ERT) or tamoxifen has been suspected, and remissions following treatment with progestins have been reported in case studies.
  • Aromatase inhibitors represent an interesting new treatment option.
  • We therefore conducted a retrospective study to evaluate the influence of hormonal treatment to ESS.
  • METHODS: Our institutional sarcoma data bank was screened for cases of ESS since 1999.
  • 5/10 patients were on ERT and 3/10 on tamoxifen at the time of diagnosis of metastatic disease.
  • Treatment strategies consisted of stopping ERT and tamoxifen, respectively, or initiation of the progestin MPA or letrozole.
  • 2/3 patients responded to MPA as first-line treatment (1 CR; 50+ months, 1 PR; 9 months).
  • 4/5 patients responded to letrozole as first-line therapy (3 PR;3+, 9+ and 10+ months) or second-line treatment after MPA (1 PR; 37+ months).
  • Survival since diagnosis of metastatic disease is 4 to 164 months.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Stromal Tumors / drug therapy. Estrogen Replacement Therapy / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Medroxyprogesterone Acetate / adverse effects. Medroxyprogesterone Acetate / therapeutic use. Middle Aged. Nitriles / adverse effects. Nitriles / therapeutic use. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Retrospective Studies. Tamoxifen / adverse effects. Tamoxifen / therapeutic use. Triazoles / adverse effects. Triazoles / therapeutic use. Uterine Neoplasms / drug therapy. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2006 Aug;102(2):413-4; author reply 414 [16712906.001]
  • (PMID = 16368128.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


22. Ishibashi M, Nakayama K, Shamima Y, Katagiri A, Iida K, Nakayama N, Miyazaki K: [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA]. Gan To Kagaku Ryoho; 2008 May;35(5):857-61
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA].
  • Endometrial stromal sarcoma (ESS) is very rare.
  • It accounts for 0.5% of all uterine corpus malignant tumors and 10% of all malignant non-epithelial tumors.
  • MPA is one effective hormonal treatment for ESS.
  • We describe two cases in which patients with metastatic low-grade ESS lesions had prolonged survival with MPA therapy.
  • Case 1 was a 50-year-old woman with a low-grade uterine endometrial stromal tumor who had been operated on at another hospital.
  • She had an incomplete response to chemotherapy.
  • We initiated MPA therapy, which resulted in significant improvement in her metastatic lesions.
  • Case 2 was a 58-year-old woman with stage Ic low-grade ESS who presented with abnormal uterine bleeding.
  • Following surgery (TAH+BSO), MPA therapy was initiated and she had no recurrence.
  • She was treated with chemotherapy, MPA and radiotherapy.
  • Her metastases improved, and the patient has continued to survive on MPA therapy alone.
  • These cases suggest that MPA might be an effective hormonal therapy for patients with low-grade ESS.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487930.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


23. Zagouri F, Linardou H, Dimopoulos AM, Papadimitriou CA: Management of advanced stage uterine sarcomas: a bone of contention. Eur J Gynaecol Oncol; 2009;30(5):483-92
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of advanced stage uterine sarcomas: a bone of contention.
  • Uterine sarcomas constitute a rare group of neoplasms characterized by an aggressive clinical course and poor prognosis.
  • It is this rarity that has resulted in clinical-trial reports and literature reviews including a broad range of histological subtypes of sarcoma.
  • Surgical resection remains the mainstay of treatment for non metastatic uterine sarcomas.
  • Although adjuvant radiation therapy has reportedly been of little survival value, it appears to improve local control and may delay recurrence.
  • The role of adjuvant chemotherapy has yet to be established; however, bearing in mind the limitations and assumptions in the pooling of data the therapeutic options should be based on the pathological subtype.
  • Considering the poor overall survival in uterine sarcomas, the need for new therapeutic agents is critical.
  • New drugs with possible activity in uterine sarcomas include trabectedin, temozolomide, liposomal doxorubicin and gemcitabine.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Neoplasm Staging. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899397.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 134
  •  go-up   go-down


24. Woytoń J, Florjański J, Tomiałowicz M: [Stromal sarcoma in pregnancy--a case report]. Ginekol Pol; 2002 Apr;73(4):400-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stromal sarcoma in pregnancy--a case report].
  • In this paper a case of a young pregnant woman with a uterine tumour of 9 cm in size, which was diagnosed as leiomyoma is presented.
  • Due to the size of the tumour, as well as its localisation--in the uterine wall in the vicinity of the big uterine vessels--an operation to excise it was postponed until after the puerperium period was over.
  • After a few weeks the patient developed intensive abdominal pains.
  • A computer tomography scan was done in which apart from swelling of the retroperitoneal lymph nodes, metastatic type changes in the lungs were also observed.
  • Suspicion of a malignant uterine tumour was confirmed during operation, however due to the extensive progress of the disease a radical operation was not possible.
  • In the histopathological examination stromal sarcoma was revealed.
  • In spite of attempts at using chemotherapy and hormonotherapy no positive effect was achieved.
  • Rapid development of the sarcoma led to the death of the patient after 4 months.
  • [MeSH-major] Endometrial Neoplasms. Pregnancy Complications, Neoplastic. Sarcoma, Endometrial Stromal
  • [MeSH-minor] Adult. Cesarean Section. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Postpartum Period. Pregnancy. Retroperitoneal Neoplasms / secondary. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12152294.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


25. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S: Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer; 2001 May;37(7):870-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
  • CAELYX/DOXIL, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types.
  • In this prospective randomised trial, 94 eligible patients with advanced soft-tissue sarcoma (STS) were treated, 50 with CAELYX (50 mg/m(2) by a 1 h intravenous (i.v.) infusion every 4 weeks) and 44 with doxorubicin (75 mg/m(2) by an i.v. bolus every 3 weeks).
  • Confirmed responses were observed with both agents: CAELYX: complete response (CR) 1 (uterine), partial response (PR) 4 (response rate (RR) 10%); and doxorubicin: CR 1, PR 3 (RR of 9%); with the best response being stable disease (NC) in 16 and 18 patients, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Doxorubicin / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Carriers. Female. Humans. Liposomes. Male. Middle Aged. Treatment Outcome


26. Bréchot JM, Kamboucher M, Brauner M, Destable MD, Duperron F, Morère JF: [Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy]. Rev Mal Respir; 2007 Jan;24(1):69-72
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy].
  • INTRODUCTION: Low grade endometrial stromal sarcoma (ESS) often expresses oestrogen (ER) and progesterone (PR) receptors, even in metastatic disease.
  • CASE REPORT: Two years after the institution of oestrogen replacement therapy (HRT) a woman of 56 presented with haemoptysis which led to the discovery of multiple pulmonary nodules.
  • Twelve years previously the patient had had a hysterectomy for a low grade endometrial stromal sarcoma, ER and PR positive.
  • Surgical resection of the nodules on the right side confirmed the diagnosis of metastatic endometrial stromal sarcoma.
  • Three months after the withdrawal of HRT and treatment with an aromatase inhibitor (letrozole) the contralateral metastases had disappeared and this complete response was maintained for more than 2 years of follow-up.
  • Hormonal treatment with aromatase inhibitors may be considered in cases where ER and PR are expressed by the primary tumour and metastases, with possible benefits even in metastatic disease.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / secondary. Triazoles / therapeutic use. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268368.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


27. Yokoyama Y, Ono Y, Sakamoto T, Fukuda I, Mizunuma H: Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection. Gynecol Oncol; 2004 Mar;92(3):999-1001
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection.
  • BACKGROUND: The endometrial stromal sarcoma (ESS) is a rare neoplasm of the uterine origin.
  • A case of a patient who successfully underwent surgical extraction of metastatic tumors of the low-grade ESS in the right ventricle is described in the present report.
  • The chemotherapy was effective against the recurrent tumors except for intracardiac site.
  • [MeSH-major] Endometrial Neoplasms / pathology. Heart Neoplasms / secondary. Heart Neoplasms / surgery. Sarcoma, Endometrial Stromal / secondary. Sarcoma, Endometrial Stromal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984976.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Toyoshima M, Okamura C, Niikura H, Ito K, Yaegashi N: Epithelioid leiomyosarcoma of the uterine cervix: a case report and review of the literature. Gynecol Oncol; 2005 Jun;97(3):957-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid leiomyosarcoma of the uterine cervix: a case report and review of the literature.
  • BACKGROUND: Epithelioid leiomyosarcomas arising from the uterine cervix are extremely rare neoplasms, with only three cases reported in the English literature.
  • Histological findings, including immunohistochemical study using desmin, SMA, cytokeratin, S-100, HMB-45, vimentin, melan-A, and CD68, led to a diagnosis of epithelioid leiomyosarcoma of the uterine cervix.
  • The patient underwent adjuvant chemotherapy and has been disease-free for over 20 months.
  • CONCLUSION: Immunohistochemical studies may be needed to differentiate among the alternative diagnoses of malignant melanoma, metastatic carcinoma, and epithelioid sarcoma.
  • [MeSH-major] Leiomyosarcoma / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890394.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


29. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M: Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol; 2010 Dec;17(12):3220-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
  • BACKGROUND: Unlike novel molecular-targeted therapies for metastatic gastrointestinal stromal tumors (GIST), conventional treatments for peritoneal sarcomatosis (PS) are mostly ineffective.
  • As with carcinomatosis of epithelial origin, a rationale base supports an aggressive locoregional treatment of PS, but the use of CRS and HIPEC in this setting is still controversial.
  • We assessed the outcome of clinically and pathologically homogeneous subsets of patients with PS uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • PS originated from GIST (pre-imatinib era) in 8 patients, uterine leiomyosarcoma (ULS) in 11, retroperitoneal liposarcoma (RPLP) in 13, and other sarcoma in 5.
  • CONCLUSIONS: Overall, results of CRS and HIPEC did not compare favorably to those of conventional therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Leiomyosarcoma / therapy. Peritoneal Neoplasms / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Liposarcoma / classification. Liposarcoma / pathology. Liposarcoma / therapy. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prospective Studies. Retroperitoneal Neoplasms / classification. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S327. Alessanrdro, Gronchi [corrected to Gronchi, Alessandro]
  • (PMID = 20585874.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Retroperitoneal liposarcoma
  •  go-up   go-down


30. Ebeling P, Eisele L, Schuett P, Bauer S, Schuette J, Moritz T, Seeber S, Flasshove M: Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. Onkologie; 2008 Feb;31(1-2):11-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
  • INTRODUCTION: Advanced stage/metastatic soft tissue sarcoma (STS) has a poor prognosis especially after failure of the established first-line treatment.
  • In patients with relapsed leiomyosarcoma, however, the combination of gemcitabine (G) and docetaxel (D) recently has emerged as a valuable salvage therapy.
  • PATIENTS AND METHODS: A retrospective analysis of G (900 mg/m2, days 1+8) and D (100 mg/m2, day 8) was performed in 34 patients with STS, and response rate (RR), overall survival (OS), time to progression (TTP), and toxicities were evaluated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Male. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2008 Feb;31(1-2):6-8 [18268393.001]
  • (PMID = 18268394.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


31. Le T: Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol; 2001 Apr;27(3):282-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population.
  • OBJECTIVES: The purpose of this study was to examine the clinical outcomes of patients with uterine carcinosarcoma and to review the role of adjuvant pelvic radiotherapy in the management of patients with high pathologic risk factors for recurrences.
  • All patients with a diagnosis of uterine carcinosarcoma from 1990-1995 were identified.
  • Eighty-four percent of patients had disease confined to the uterus at the time of evaluation.
  • Patients with high-grade (2, 3) adenocarcinoma, deep myometrial invasion, or gross pelvic metastatic disease were offered adjuvant pelvic irradiation.
  • CONCLUSION: Uterine carcinosarcoma is a rare and aggressive form of uterine malignancy even in early stages.
  • The role of chemotherapy deserves further investigation as all recurrences were in the upper abdominal and distant locations outside of the radiation field.
  • PRECIS: Uterine sarcoma has a poor prognosis even in early stage.
  • [MeSH-major] Carcinosarcoma / mortality. Carcinosarcoma / radiotherapy. Uterine Neoplasms / mortality. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Pelvis / radiation effects. Prognosis. Radiotherapy, Adjuvant. Reference Values. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11373106.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Hensley ML: Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol; 2010 Jul;22(4):356-61
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
  • PURPOSE OF REVIEW: The combination of fixed-dose-rate gemcitabine and docetaxel has become an established treatment option for advanced uterine leiomyosarcoma and has demonstrated efficacy in nonleiomyosarcoma histology soft-tissue sarcomas.
  • The activity of this regimen in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatric sarcomas is discussed.
  • RECENT FINDINGS: Fixed-dose-rate gemcitabine and docetaxel achieved high objective response rates in three prospective phase II studies as first-line or second-line therapy for advanced uterine leiomyosarcoma.
  • In a randomized trial, the combination of gemcitabine and docetaxel was superior to gemcitabine alone in terms of objective response, progression-free, and overall survival among patients with soft-tissue sarcoma, most of whom had received at least one prior cytotoxic regimen.
  • In a small, prospective phase II trial for women with completely resected stage I, II, III, or IV high-grade uterine leiomyosarcoma, adjuvant treatment with gemcitabine-docetaxel was associated with a 2-year progression-free survival rate that appears superior to that of historical controls.
  • SUMMARY: Fixed-dose-rate gemcitabine and docetaxel is a reasonable treatment option for patients with advanced soft-tissue sarcoma.
  • The regimen is a good choice as first-line or second-line therapy for advanced uterine leiomyosarcoma.
  • The role of adjuvant gemcitabine-docetaxel in completely resected, uterine-limited, high-grade leiomyosarcoma is under investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Humans. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20520541.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 34
  •  go-up   go-down


33. Brain EG: Safety and efficacy of ET-743: the French experience. Anticancer Drugs; 2002 May;13 Suppl 1:S11-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial evidence of clinical benefit with ecteinascidin-743 (ET-743) in patients with sarcoma was provided during a Phase I pharmacokinetic study in which 52 patients received ET-743 at doses of 50-1800 micrograms/m2 as a 24 h continuous infusion every 3 weeks.
  • Neutropenia and thrombocytopenia were the dose-limiting toxicities; liver toxicity (a severe but transient and reversible increase in transaminase concentrations) was not treatment limiting.
  • In conjunction with results obtained with ET-743 in a compassionate-use program, these indications of activity in heavily pretreated patients with sarcoma prompted initiation of a French multicenter Phase II study of ET-743 in this population.
  • From February 1999 to January 2001, 54 patients with advanced anthracycline-pretreated soft-tissue sarcoma (STS) received ET-743 at a dose of 1500 micrograms/m2 every 3 weeks by continuous 24 h infusion.
  • The main histological subtype was leiomyosarcoma (37%); the majority of primary tumors were visceral (24%) or uterine (19%) sarcomas.
  • In this Phase II population (> or = 25% negative prognostic or predictive factors of response to chemotherapy; > or = 50% anthracycline- and ifosfamide-resistant), safety data were comparable to those obtained in the Phase I and compassionate-use studies.
  • The response rate was uninfluenced by tumor metastatic site, size or anthracycline sensitivity status.
  • These results, combined with the lack of cumulative toxicity, confirm the role of ET-743 in the treatment of advanced STS.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / therapeutic use. Isoquinolines / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Disease-Free Survival. Drug Administration Schedule. France. Humans. Infusions, Intravenous. Multicenter Studies as Topic. Survival Analysis. Tetrahydroisoquinolines. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12173489.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  • [Number-of-references] 12
  •  go-up   go-down


34. Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG: A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol; 2000 Nov;79(2):147-53
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival.
  • METHODS: Patients were randomized to receive ifosfamide (1.5 g/m(2)/day) times 5 days every 3 weeks for eight courses with mesna uroprotection, with or without cisplatin (20 mg/m(2)/day) times 5 days.
  • No patient had received previous chemotherapy.
  • Percentages of adverse effects reported in 191 patients receiving chemotherapy included (ifosfamide/cisplatin-ifosfamide) grade 3 or 4 granulocytopenia (36/60), grade 3 or 4 anemia (8/17), grade 3 or 4 central nervous system toxicity (19/14), and grade 3 or 4 peripheral neuropathy (1/12).
  • Treatment may have contributed to the deaths of 6 patients treated with full doses of ifosfamide and cisplatin for 5 days.
  • The proportion of patients responding to ifosfamide alone versus ifosfamide-cisplatin therapy was (0.36 versus 0.54) overall, 0.47 versus 0.61 for pelvic, 0.21 versus 0.54 for lung, and 0.33 versus 0.40 for "other" metastatic sites of measurable disease.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Ifosfamide / therapeutic use. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • [CommentIn] Gynecol Oncol. 2000 Nov;79(2):145-6 [11063635.001]
  • (PMID = 11063636.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


35. Ferraresi V, Ciccarese M, Cercato MC, Nuzzo C, Zeuli M, Di Filippo F, Giannarelli D, Cognetti F: Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol; 2008 Dec;63(1):149-55
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
  • PURPOSE: To explore the clinical activity and toxicity of gemcitabine infused at the fixed dose of 10 mg/m(2)/min over 100 min in patients with soft tissue sarcomas (STSs).
  • PATIENTS AND METHODS: Fourteen patients with advanced locally unresectable and/or metastatic, pretreated STSs (seven leiomyosarcoma, three malignant schwannoma, one synovialsarcoma, one malignant fibrous histiocytoma, one endometrial stromal cell sarcoma, one undifferentiated) were treated with gemcitabine 10 mg/m(2)/min/week over 100 min given for 3 weeks out of 4.
  • The median number of previous medical treatments for advanced disease was 1 (range 1-2).
  • Treatment was well tolerated and the main causes of dose-reduction or omission/delay were hematological and liver toxicities.
  • One patient (7%; 95% confidence interval: 0.2-33.9%) with a metastatic uterine leiomyosarcoma obtained a partial response that lasted for 6.5 months.
  • The median time to progression was 3.1 months (range 1.0-9.5).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease Progression. Dose-Response Relationship, Drug. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351342.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


36. Seo JB, Im JG, Goo JM, Chung MJ, Kim MY: Atypical pulmonary metastases: spectrum of radiologic findings. Radiographics; 2001 Mar-Apr;21(2):403-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinoma is regarded as the most common cell type of a cavitating metastasis, but metastatic nodules from adenocarcinomas and sarcomas also cavitate occasionally.
  • Calcification can occur in a metastatic sarcoma or adenocarcinoma, which makes differentiation from a benign granuloma or hamartoma difficult.
  • Even though tumor emboli in pulmonary arteries can be seen at computed tomography, diagnosis is difficult because they are located in small or medium arteries.
  • Dilated vascular structures within the mass can be seen in metastatic sarcomas.
  • A sterilized metastasis after chemotherapy is radiologically indistinguishable from a residual viable tumor.
  • Benign tumors such as uterine leiomyomas and giant cell tumors of the bone rarely metastasize to the lung.
  • [MeSH-major] Lung Neoplasms / secondary. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11259704.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


37. Brassens S, Chevalier JM, Leblainvaux M: [A strange case of phlebitis]. Ann Cardiol Angeiol (Paris); 2003 Dec;52(6):375-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This sarcoma developed from the smooth muscle of a leg vessel, probably a vein.
  • Leiomyosarcoma is a malignant mesenchymal tumor of specialized connective tissue, with a strong potential for local proliferation and metastatic spread.
  • It usually involves the uterine muscle or the wall of the digestive tract, as well as the large vessels of the abdomen and thorax, the prostate very seldom, and only exceptionally a peripheral vein as in this case.
  • The treatment is surgical when possible, associated with radiotherapy and chemotherapy as appropriate.
  • The prognosis is especially poor when the diagnosis is made at the metastatic stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14752921.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A: Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer; 2003 Sep;39(13):1842-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventy-two adults with metastatic or advanced solid tumours received ET-743 in escalating doses between 50 and 1100 microg/m(2), initially as a 1-h infusion, and later at doses between 1000 and 1800 microg/m(2) as a 3-h infusion every 3 weeks.
  • One pCR (melanoma), CR (uterine leiomyosarcoma), one PR (colon stromal sarcoma) and a MR (37% tumour shrinkage, gastric stromal sarcoma) were observed.
  • A further 9 patients with colorectal, mesothelioma, bile duct carcinoma and bladder cancer had SD which lasted for six or more treatment cycles.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacokinetics. Dioxoles / pharmacokinetics. Isoquinolines / pharmacokinetics. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Dose-Response Relationship, Drug. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Tetrahydroisoquinolines

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12932661.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  •  go-up   go-down


39. Fleming GF: Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol; 2007 Jul 10;25(20):2983-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma / drug therapy. Medical Oncology / methods. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Disease-Free Survival. Female. Humans. Neoplasm Metastasis. Sarcoma / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2007 Nov 1;25(31):5048
  • (PMID = 17617530.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 82
  •  go-up   go-down






Advertisement